Risk Factors for Length of Hospital Stay in Acute Exacerbation Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study

References

• Wang H, Naghavi M, Allen C. A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. doi:10.1016/S0140-6736(16)31012-1
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• (GOLD). GIfCLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2020). Available from: https://goldcopdorg/gold-reports/2020. Accessed March 18, 2022.
   Google Scholar
• Ozkaya S, Findik S, Atici AG. The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease. Clinicoecon Outcomes Res. 2011;3:15–18. doi:10.2147/CEOR.S14820
   PubMedGoogle Scholar
• Alshabanat A, Otterstatter MC, Sin DD, et al. Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates. Int J Chron Obstruct Pulmon Dis. 2017;12:961–971. doi:10.2147/COPD.S124385
   PubMed Web of Science ®Google Scholar
• Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020;25(3):259–266. doi:10.1111/resp.13660
   PubMed Web of Science ®Google Scholar
• Milan S, Bondalapati P, Megally M, et al. Positive expiratory pressure therapy with and without oscillation and hospital length of stay for acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:2553–2561. doi:10.2147/copd.S213546
   PubMed Web of Science ®Google Scholar
• Genao L, Durheim MT, Mi X, Todd JL, Whitson HE, Curtis LH. Early and long-term outcomes of older adults after acute care encounters for chronic obstructive pulmonary disease exacerbation. Ann Am Thorac Soc. 2015;12(12):1805–1812. doi:10.1513/AnnalsATS.201504-250OC
   PubMed Web of Science ®Google Scholar
• You L, Niu H, Huang K, Dong F, Yang T, Wang C. Clinical features and outcomes of acute exacerbation in chronic obstructive pulmonary disease patients with pulmonary heart disease: a multicenter observational study. Int J Chron Obstruct Pulmon Dis. 2021;16:2901–2910. doi:10.2147/copd.S325925
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/copd.S234942
   PubMed Web of Science ®Google Scholar
• Torabipour A, Hakim A, Ahmadi Angali K, Dolatshah M, Yusofzadeh M. Cost analysis of hospitalized patients with chronic obstructive pulmonary disease: a State-Level Cross-Sectional Study. Tanaffos. 2016;15(2):75–82.
   PubMedGoogle Scholar
• Li F, Sun Z, Li H, Yang T, Shi Z. Factors associated with hospitalisation costs in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2018;22(4):458–463. doi:10.5588/ijtld.17.0430
   PubMed Web of Science ®Google Scholar
• Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002;165(5):704–707. doi:10.1164/ajrccm.165.5.2104055
   PubMed Web of Science ®Google Scholar
• Koul PA, Nowshehr AA, Khan UH, Jan RA, Shah SU. Cost of severe chronic obstructive pulmonary disease exacerbations in a High Burden Region in North India. Ann Glob Health. 2019;85(1). doi:10.5334/aogh.2423
   PubMed Web of Science ®Google Scholar
• Dalal AA, Christensen L, Liu F, Riedel AA. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341–349. doi:10.2147/COPD.S13771
   PubMedGoogle Scholar
• Chen YH, Yao WZ, Cai BQ, et al. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J (Engl). 2008;121(7):587–591. doi:10.1097/00029330-200804010-00003
   PubMed Web of Science ®Google Scholar
• Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C, Kotanidou A. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med. 2009;24(9):1043–1048. doi:10.1007/s11606-009-1061-2
   PubMed Web of Science ®Google Scholar
• Limsuwat C, Mankongpaisarnrung C, Dumrongmongcolgul N, Nugent K. Factors influencing the length of hospital stay in patients with acute exacerbations of chronic obstructive pulmonary disease admitted to intensive care units. Qual Manag Health Care. 2014;23(2):86–93. doi:10.1097/qmh.0000000000000024
   PubMed Web of Science ®Google Scholar
• Mushlin AI, Black ER, Connolly CA, Buonaccorso KM, Eberly SW. The necessary length of hospital stay for chronic pulmonary disease. JAMA. 1991;266(1):80–83. doi:10.1001/jama.1991.03470010084035
   PubMed Web of Science ®Google Scholar
• Agboado G, Peters J, Donkin L. Factors influencing the length of hospital stay among patients resident in Blackpool admitted with COPD: a cross-sectional study. BMJ Open. 2012;2(5):e000869. doi:10.1136/bmjopen-2012-000869
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Ielpo A, Barbeta E, et al. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. Respir Res. 2018;19(1):261. doi:10.1186/s12931-018-0951-4\]
   PubMed Web of Science ®Google Scholar
• Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J Chron Obstruct Pulmon Dis. 2014;9:99–105. doi:10.2147/COPD.S51467
   PubMed Web of Science ®Google Scholar
• Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, et al. Predictors of hospital length of stay in patients with exacerbations of COPD: a Cohort Study. J Gen Intern Med. 2015;30(6):824–831. doi:10.1007/s11606-014-3129-x.
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2):347–382. doi:10.1086/313954
   PubMed Web of Science ®Google Scholar
• Lim WS, Woodhead M. British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax. 2011;66(6):548–549. doi:10.1136/thoraxjnl-2011-200081
   PubMed Web of Science ®Google Scholar
• Dai G, Ran Y, Wang J, et al. Clinical differences between eosinophilic and noneosinophilic acute exacerbation of chronic obstructive pulmonary disease: a Multicenter Cross-Sectional Study. Mediators of Inflammation. 2020;2020:1059079. doi:10.1155/2020/1059079
   PubMed Web of Science ®Google Scholar
• Cao B, Huang Y, She DY, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320–1360. doi:10.1111/crj.12674
   PubMed Web of Science ®Google Scholar
• Claessens YE, Debray MP, Tubach F, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192(8):974–982. doi:10.1164/rccm.201501-0017OC
   PubMed Web of Science ®Google Scholar
• Flateau C, Le Bel J, Tubiana S, et al. High heterogeneity in community-acquired pneumonia inclusion criteria: does this impact on the validity of the results of randomized controlled trials? BMC Infect Dis. 2018;18(1):607. doi:10.1186/s12879-018-3515-9
   PubMed Web of Science ®Google Scholar
• Shujaat A, Minkin R, Eden E. Pulmonary hypertension and chronic cor pulmonale in COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(3):273–282.
   PubMedGoogle Scholar
• Park SY, Lee CY, Kim C, et al. One-year prognosis and the role of brain natriuretic peptide levels in patients with chronic cor pulmonale. J Korean Med Sci. 2015;30(4):442–449. doi:10.3346/jkms.2015.30.4.442
   PubMed Web of Science ®Google Scholar
• Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–382. doi:10.3109/15412555.2010.510160
   PubMedGoogle Scholar
• Inabnit LS, Blanchette C, Ruban C. Comorbidities and length of stay in chronic obstructive pulmonary disease patients. COPD. 2018;15(4):355–360. doi:10.1080/15412555.2018.1513470
   PubMedGoogle Scholar
• Harries TH, Thornton HV, Crichton S, Schofield P, Gilkes A, White PT. Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis. 2015;10:603–611. doi:10.2147/copd.S77092
   PubMed Web of Science ®Google Scholar
• Engel B, Schindler C, Leuppi JD, Rutishauser J. Predictors of re-exacerbation after an index exacerbation of chronic obstructive pulmonary disease in the REDUCE randomised clinical trial. Swiss Med Wkly. 2017;147:w14439. doi:10.4414/smw.2017.14439
   PubMed Web of Science ®Google Scholar
• Li LS, Caughey G, Johnston K. Comorbidity associated with referral to pulmonary rehabilitation in people hospitalized with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2014;34(6):430–436. doi:10.1097/HCR.0000000000000080
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. doi:10.1183/09031936.00128008
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10(1):45. doi:10.1186/1465-9921-10-45
   PubMed Web of Science ®Google Scholar
• Abusaid GH, Barbagelata A, Tuero E, Mahmood A, Sharma G. Diastolic dysfunction and COPD exacerbation. Postgrad Med. 2009;121(4):76–81. doi:10.3810/pgm.2009.07.2033
   PubMed Web of Science ®Google Scholar
• Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC
   PubMed Web of Science ®Google Scholar
• Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913–921. doi:10.1056/NEJMoa1203830
   PubMed Web of Science ®Google Scholar
• Caramori G, Casolari P, Barczyk A, Durham AL, Di Stefano A, Adcock I. COPD immunopathology. Semin Immunopathol. 2016;38(4):497–515. doi:10.1007/s00281-016-0561-5
   PubMed Web of Science ®Google Scholar
• Rahimirad S, Ghaffary MR, Rahimirad MH, Rashidi F. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease. Tuberk Toraks. 2017;65(1):25–31. doi:10.5578/tt.27626
   PubMed Web of Science ®Google Scholar
• Gómez-Rosero JA, Cáceres-Galvis C, Ascuntar J, Atencia C, Vallejo CE, Jaimes F. Biomarkers as a prognostic factor in COPD exacerbation: a Cohort Study. COPD. 2021;18(3):325–332. doi:10.1080/15412555.2021.1922370
   PubMedGoogle Scholar
• Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:2721–2730. doi:10.2147/copd.S170353
   PubMed Web of Science ®Google Scholar
• Lu FY, Chen R, Li N, et al. Neutrophil-to-lymphocyte ratio predicts clinical outcome of severe acute exacerbation of COPD in frequent exacerbators. Int J Chron Obstruct Pulmon Dis. 2021;16:341–349. doi:10.2147/copd.S290422
   PubMed Web of Science ®Google Scholar
• Taylan M, Demir M, Kaya H, et al. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients. Clin Respir J. 2017;11(3):311–317. doi:10.1111/crj.12336
   PubMed Web of Science ®Google Scholar